Takeda launches IBS unbranded site

Share this article:
Takeda launches IBS unbranded site
Takeda launches IBS unbranded site

Takeda is observing Irritable Bowel Syndrome (IBS) Awareness Month with the launch of an unbranded website for patients called Let's Talk IBS. Campaign materials include a video featuring Dr. Lauren Gerson, along with tips, treatment options and other interactive areas for patients.

The campaign uses visual metaphors to describe how IBS sufferers feel, with images of people holding dart boards, knotted rope, inner tubes and pressurized gas tanks to their abdomens. In one section of the website, visitors can drag and drop similar images onto a blank T-shirt to describe their experience with the disorder. Ketchum is a PR partner on the campaign.

The creative for the Let's Talk campaign is reminiscent of the much discussed (and much recalled) ads for Novartis' Zelnorm, which introduced bare stomachs as a medium for messaging. FDA took Zelnorm off the market in 2007, citing cardiovascular risks.    

Takeda markets Amitiza in the US through a partnership with Sucampo Pharma Americas. Under the "Treatment Options" tab at Letstalkibs.com, visitors will find a link to Amitiza.com down at the bottom of the page, beneath other suggested treatments for IBS including OTC treatments, antispasmodics and antidepressants.   

Sales of Amitiza (lubiprostone) were up 8.2% in 2009, to $209.2 million, according to a Sucampo annual report. Fresh branded creative is in the works.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...